TELO (Telomir Pharmaceuticals) Notes Receivable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Notes Receivable?

Telomir Pharmaceuticals's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Telomir Pharmaceuticals Notes Receivable Historical Data

The historical data trend for Telomir Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Notes Receivable Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Notes Receivable

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Notes Receivable	Get a 7-Day Free Trial							-	-	-	-	-

Telomir Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Telomir Pharmaceuticals Notes Receivable Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 South East, 2nd Street, Suite 200, No.1009, Miami, FL, USA, 33131

Website

https://www.telomirpharma.com

Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.